Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31527327 | 0.90 | ARG1 (0.40) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL15012107 | 0.81 | CYP4F2 (0.44) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL26694474 | 0.80 | ARG1 (0.40) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11652154 | 0.80 | CYP2D6 (0.48) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL25329101 | 0.78 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL15567482 | 0.78 | ARG1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23053580 | 0.78 | ARG1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5928282 | 0.78 | ARG1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL12909915 | 0.77 | ARG1 (0.38) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL26120445 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4352061-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | Redx Pharma Plc (GB) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347589-A2 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS | Redx Pharma Plc (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-117460730-A | Pyrido [4,3-D ] pyrimidine compounds capable of inhibiting KRAS muteins | 莱德克斯制药公共有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117425658-A | Quinazoline derivatives as RAS inhibitors | 莱德克斯制药公共有限公司 | 2024-01-19 | — | — | CN | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648452-A | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022258974-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | REDX PHARMA PLC (GB) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022248885-A2 | COMPOUNDS | REDX PHARMA PLC. (GB) | 2022-12-01 | — | — | WO | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022170947-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS KRAS MUTANT G12C INHIBITORS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-113999226-A | Heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | KRAS, NRAS, HRAS | ARG1 3923/4885ARG2 4593/4885CYP2D6 896/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ARG1 4028/4885ARG2 4472/4885CYP2D6 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.